Press Releases BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Delayed Toronto S.E. Other stock markets 03:24:20 2024-04-26 pm EDT			5-day change	1st Jan Change
2.93 ^CAD	-2.66%		+2.45%	-62.44%

Apr. 24	BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	MT
Apr. 10	BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BriaCell Announces Oral and Poster Presentations at ASCO 2024	Apr. 24	AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer	Apr. 10	AQ
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR	Apr. 09	AQ
BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K	Apr. 02	PU
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies	Mar. 07	AQ
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference	Mar. 06	AQ
BriaCell Provides Update on Alleged Illegal Trading of Public Securities	Feb. 27	AQ
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	Feb. 07	AQ
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing	Feb. 06	AQ
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting	Jan. 30	AQ
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer	Jan. 04	AQ
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	Dec. 28	AQ
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset	Dec. 20	AQ
BriaCell Therapeutics : BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2023 - Form 8-K	Dec. 14	PU
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS	Dec. 06	AQ
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit	Dec. 06	AQ
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor	Nov. 30	AQ
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND	Nov. 03	AQ
BriaCell Therapeutics : BRIAPRO THERAPEUTIC CORP. FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2023 - Form 8-K	23-10-25	PU
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate	23-10-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Press Releases

Filters